A Phase II Trial of TAS-102 (Lonsurf) in Patients With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma After Progression Through First Line Chemotherapy

Trial Profile

A Phase II Trial of TAS-102 (Lonsurf) in Patients With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma After Progression Through First Line Chemotherapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Nov 2017

At a glance

  • Drugs Tipiracil/trifluridine (Primary)
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Nov 2017 Planned End Date changed from 1 Oct 2020 to 1 Nov 2020.
    • 06 Nov 2017 Planned primary completion date changed from 1 Oct 2019 to 1 Nov 2019.
    • 02 Oct 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top